2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Surgical, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

6153 Maintaining continuity of hemato-oncologic care during active conflict: A matched-period comparison at a tertiary medical center

Yotam Bronstein, M.D, Libi Feigin, M.D2, Yael C. Cohen, MD3, Svetlana Trestman, MD4, Yakir Moshe, MD, PhD5, Chava Perry, MD, PhD6, Irit Avivi Mazza, MD7
2 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
3 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
4 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
5 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
6 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

Background:
Patients with hematologic malignancies require continuous access to intensive treatment, hematopoietic stem-cell transplantation (HSCT), cellular therapy, clinical trials, and supportive care. However, evidence regarding the maintenance of specialized hematology services during armed conflict remains limited. We evaluated whether a predefined hematology-specific emergency preparedness plan, could preserve the delivery of time-sensitive care during sustained emergency conditions.

Methods:
We conducted a retrospective, single-center comparative cohort study at a tertiary academic medical center, comparing all hematology activity during a 40-day emergency period in 2026 with that of the corresponding calendar period in 2025.

Prior to the conflict, the hospital leadership and the hematology division jointly developed a comprehensive deployment plan. The plan defined the relocation and protected operation of inpatient, outpatient clinic, and day-care services; established patient prioritization and triage processes, including consolidation of visits and treatments, and set out virtual follow-up pathways, communication procedures, infection-control monitoring, and supportive services.

Preparatory multidisciplinary meetings were conducted to establish workflows and ensure operational readiness. Outcomes included clinic, day-care, and inpatient activity; HSCT and chimeric antigen receptor T-cell (CAR-T) therapy; clinical-trial enrollment; microbiological surveillance; hospital length of stay and mortality.

Results:
Upon declaration of the emergency, the predefined plan was activated as designed. Within three hours, Inpatient services were relocated to protected double-occupancy rooms, reducing capacity by 31.0%, from 29 to 20 beds. Clinic activity continued in its original location using protected access pathways and nearby shelters, whereas day-care activity was transferred to a partially protected area with immediate access to shelter. Pre-visit triage, fast-track pathways, visit and treatment consolidation and virtual follow-up were implemented according to the preparedness plan.

Hospitalizations decreased from 89 to 67 (−24.7%), closely paralleling the reduction in available beds. Clinic encounters decreased from 3,296 to 2,585 (−21.6%). By contrast, day-care activity was largely preserved: encounters decreased from 2,087 to 1,795 (−14.0%), while the number of individual day-care patients decreased only from 882 to 843 (−4.4%). Patient demographics and disease distributions were comparable between the two periods, with lymphoproliferative diseases accounting for the majority of hemato-oncologic patients receiving active treatment. Clinical-trial enrollment was maintained, with 25 patients enrolled during the routine period and 24 during the emergency period. CAR-T activity was fully preserved, with 7 infusions performed in each period. Allogeneic HSCT activity was also largely maintained, with 5 procedures during the routine period and 3 during the emergency period, although total HSCT volume decreased from 9 to 4. Among hospitalized patients, weekly screening for vancomycin-resistant Enterococcus and carbapenem-resistant Enterobacterales was maintained, with no newly acquired colonization identified. Median hospital length of stay did not differ significantly between periods (5.04 vs 4.67 days; P=.40). Thirty-day mortality was also similar (7.9% vs 6.0%; risk ratio, 0.76; 95% CI, 0.23–2.49; P=.76).

Conclusions:
A predefined and rapidly activated hematology-specific emergency preparedness plan preserved access to time-sensitive hematologic care despite a substantial reduction in inpatient capacity. Planned relocation to protected facilities, prioritization of ambulatory treatment, maintenance of CAR-T therapy and clinical-trial access, coordinated communication, and rigorous infection-control measures enabled the continuity of advanced hematology services without evidence of worse short-term clinical outcomes. This model provides a practical framework for hematology preparedness during armed conflict and other major healthcare disruptions.

Irit Avivi Mazza, MD: Takeda - Honoraria; Medison - Honoraria; Novartis - Honoraria; AbbVie Inc. - Honoraria; MSD - Honoraria; Gilead - Consultancy (Includes expert testimony); Roche - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Janssen - Consultancy (Includes expert testimony); MSD - Consultancy (Includes expert testimony); PhenoTA - Consultancy (Includes expert testimony)